AlphAIalphai — Financial news for AI agents
fool.comAUG 86 min read$ATR

Aptar (ATR) Q2 2026 Earnings Call Transcript

AptarGroup (ATR) reported Q2 2026 total sales of $1.03B, up 6% reported, with adjusted EPS of $1.42 above guidance. Adjusted EBITDA was $213M, down 3%, and margins fell due to mix and operational issues in beauty. Pharma core sales grew 8% excluding emergency medicine destocking. Net debt was $1.2B, leverage 1.49x, and Q3 adjusted EPS guidance is $1.45 to $1.53.

Original reporting
fool.com
Published Aug 8, 2026, 4:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 4:55 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aptar (ATR) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$ATRBullishMed
01

Why it matters

For ATR, the key tradable items are the reported quarterly metrics (revenue, adjusted EPS, EBITDA/margins), the stated full-year emergency medicine headwind, and the explicit Q3 adjusted EPS guidance range. Additional catalysts include a favorable court ruling, a UK device approval for a next-gen propellant, and FDA guidance changes for generic inhaled therapies.

02

Market read

ATR’s call combines a revenue milestone and EPS beat with clear forward guidance and multiple margin headwinds, creating a balanced setup for earnings-driven positioning.

03

What to watch

North America operational issues and beauty resin pass-through timing lag are explicitly cited; traders may underweight how these can pressure EBITDA margin even if top-line growth holds.

Relevance 8/10Novelty 7/10Timing: pre-market today, ahead of trading on the earnings call transcript

Background

This is a transcript-style summary of AptarGroup’s Q2 2026 earnings call, covering segment performance, margins, guidance, and management commentary on operational and regulatory developments.

Company-level read

Ticker impact

$ATRBullishMedium confidence
Context

Aptar reported Q2 2026 revenue above $1B, adjusted EPS of $1.42, and guided Q3 adjusted EPS to $1.45-$1.53.

Expected impact

Likely near-term volatility with a bias to upside if investors focus on the EPS beat and Q3 range, but margin headwinds (beauty mix, North America issues) can cap the reaction.

Evidence & confidence

The article discloses multiple decision-relevant datapoints: revenue threshold break, adjusted EPS above guidance, segment margin declines, and a specific Q3 EPS outlook. Offsetting factors include EBITDA margin compression and a stated emergency medicine headwind.

Market effects

Sector

Signals ongoing demand strength in pharma delivery (asthma/CNS) while highlighting margin sensitivity to product mix and resin cost pass-through in consumer/beauty.

Regional

North America underperformance and Brazil customer share shifts are flagged as active operational issues that could affect regional revenue and margins.

Global

FDA generic inhaled-therapy guidance update and UK approval for a next-gen propellant device may support broader inhalation market growth expectations for delivery-component suppliers.

Counterpoint

What could challenge this read

The EPS beat may be partly mix and timing-driven, while disclosed margin compression and the $65M emergency medicine headwind could dominate forward estimates.

Key entities

  • company
    AptarGroup, Inc.

    Reported Q2 2026 results, provided Q3 adjusted EPS guidance, and discussed segment margin drivers and operational issues.

  • company
    ARS Pharmaceuticals

    Referenced as the counterparty in litigation where Aptar reported a favorable court ruling.

  • person
    Gael Touya

    CEO designate who will succeed Stephan Tanda on Sept. 1, 2026; discussed propellant transition and generic inhaled-therapy market implications.

  • person
    Stephan Tanda

    CEO retiring Sept. 1, 2026; cited North America operational issues and Brazil customer share shifts.

Read at source← All news

Related articles

JUL 30
$ATRMed

APTARGROUP, INC. (ATR): Results of Operations and Financial Condition

APTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atr-20260630x8kexx991.htm EX-99.1 Document Exhibit 99.1 Aptar Reports Second Quarter 2026 Results Crystal Lake, Illinois, July 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing,

SEC EDGAR 8-K6 min
AUG 8
$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

yahoo.com4 min
AUG 8
$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

fool.com6 min
AUG 8
$FTSMed

Fortis (FTS) Q2 2026 Earnings Call Transcript

Fortis (FTS) reported Q2 2026 net earnings of C$396 million, up C$26 million year over year, and EPS of C$0.78. Capital expenditures were C$2.7 billion through June, with a C$5.6 billion 2026 plan. Management reiterated 4% to 6% dividend growth through 2030 and cited Tilbury LNG Phase 1B approval and a 9.75% ROE request in an Arizona rate case.

fool.com7 min
AUG 8
$ANMed

AutoNation (AN) Q2 2026 Earnings Call Transcript

AutoNation (AN) reported Q2 2026 adjusted diluted EPS of $5.56, up 2% year over year, with total revenue of $6.93 billion, essentially flat. After-sales gross profit was a record $607 million, and Customer Financial Services profitability rose to $2,800 per vehicle. ANF net income increased to $11 million and the portfolio grew to $2.67 billion. The company repurchased $457 million of shares and acquired four stores.

fool.com6 min
AUG 8
$DOCMed

Healthpeak Properties Q2 Earnings Call Highlights

Healthpeak Properties (NYSE:DOC) highlighted Q2 results and updates on capital recycling and leasing. It recapitalized a Brookfield outpatient portfolio, retaining 51% interest and raising $1B cash, and noted a 5.9% trailing cash cap rate. Lab occupancy rose to 78.5%. Net debt/adj. EBITDA was 4.7x with $4.1B liquidity; it repaid $900M debt and repurchased $100M shares.

yahoo.com6 min